Beyond CFUs: Rethinking What a Probiotic Can Do
How Propionibacterium freudenreichii P.UF1® Connects Microbial Metabolism, Microbial Ecology and Immune Signaling
For decades, probiotics have largely been compared by two familiar measures: which organisms are included and how many colony-forming units are delivered. Those measures still matter—but they do not answer the question that may matter most clinically:
What is the organism actually capable of doing once it reaches the intestinal ecosystem?
A next-generation probiotic framework looks beyond microbial presence and asks about microbial function: Can the organism survive gastrointestinal stress? Can it remain metabolically active? Which nutrients and metabolites can it generate? Can those metabolites participate in cross-feeding? Does the organism communicate with host pathways? And is there strain-specific research connecting those functions to measurable biological outcomes?
Propionibacterium freudenreichii P.UF1®—commercially available as ProGenr8®—has an unusually compelling story because its research program spans this entire continuum: discovery in the early-life microbiome, strain-specific metabolic activity, peer-reviewed mechanistic work, referenced preclinical models and emerging human clinical research.
That combination makes P.UF1® more than an exercise in adding another probiotic strain. It provides a model for a different way of thinking about probiotics: select organisms for the functions they contribute to the ecosystem
A Discovery Story Rooted in the Early-Life Microbiome
P.UF1® was identified through University of Florida research examining the intestinal microbiota associated with preterm infants receiving human breast milk. The subsequent research program focused on why microbiota associated with breast-milk feeding produced a different immune phenotype than microbiota associated with formula feeding.
In transfaunation experiments, microbiota from human breast-milk-fed infants transferred to germ-free mice was associated with increases in protective Th17 cells and regulatory T cells, while formula-fed microbiota did not produce the same immune effects. In the preclinical model, addition of P.UF1® to the formula-fed microbial community was associated with changes in the immune parameters evaluated in the study.[1]
That observation helped shift the scientific question from “Which bacteria are present?” to “Which organism is contributing a function that changes the behavior of the ecosystem?”
Beyond Survival: Generating Function Inside the Gut
P.UF1® is metabolically active. The ProGenr8® research materials describe production of B vitamins, short-chain fatty acids including propionate and acetate, and amino acids including tryptophan, tyrosine and phenylalanine. Propionibacteria are also known for metabolic capabilities that include production of enzymes and other compounds relevant to microbial ecology.
The significance is not that every metabolite automatically produces a clinical outcome. The more important concept is ecological: a probiotic organism can contribute substrates and signals that may be used by other organisms within the intestinal community.
This is microbial cross-feeding—and it changes how a probiotic can be evaluated.
A Metabolically Active Probiotic
Propionibacterium freudenreichii possesses extensive metabolic capabilities that distinguish it from many conventional probiotic organisms. The P.UF1® research program describes metabolic activity involving vitamins, short-chain fatty acids, amino acids and other microbial metabolites.
For P.UF1®, this metabolic story includes several particularly relevant areas:
B Vitamins — P.UF1® research materials characterize vitamin-related metabolic activity, including B-vitamin pathways. This moves the probiotic conversation beyond simply delivering a microorganism toward understanding what that organism can contribute through its biological activity.
Propionate + Acetate — Propionate and acetate are important outputs of propionibacterial metabolism and provide a clear example of how a viable organism can contribute metabolites within the intestinal environment.
Amino-Acid Metabolism — P.UF1® research materials also describe metabolic activity involving amino acids and amino-acid-derived compounds, expanding the potential interactions between the strain and its surrounding microbial ecosystem.
Microbial Cross-Feeding — Metabolites produced by one organism can become substrates or signals for other members of the microbial community. This creates the potential for P.UF1® to influence the intestinal ecosystem not simply through its presence, but through the metabolic activity it contributes to the community around it.
From Probiotic Presence to Probiotic Function
This distinction changes the way probiotic value can be considered.
A microorganism that survives gastrointestinal transit has achieved presence.
A microorganism that remains metabolically active and contributes biologically relevant compounds has the potential to contribute function.
That is an important part of the P.UF1® story.
SURVIVE → METABOLIZE → GENERATE → CROSS-FEED → SIGNAL
Rather than asking only how many CFUs reach the intestine, a function-first approach asks what biological capabilities arrive with them.
Human Research Adds Another Layer
The metabolic story is also being explored in humans. In a randomized, double-blind, placebo-controlled four-week study described in the ProGenr8® research materials, 20 adults received either 10 billion CFU of P.UF1® or placebo, with plasma vitamin K1 evaluated during the intervention.
The study provides an important bridge between the strain’s characterized metabolic capabilities and the investigation of measurable biological outcomes in humans. It also illustrates a broader principle that becomes increasingly important throughout the P.UF1® story:
The value of a probiotic may depend not only on whether it survives—but on what it does after it arrives.
The Pantryome: A Different Way to Think About Probiotic Value
One useful concept in the ProGenr8® program is the “pantryome”: the idea that certain microbes can function as metabolic suppliers within the intestinal community. Instead of considering a probiotic only as an organism occupying space, this framework asks what metabolic resources it may contribute to the surrounding ecosystem.
Vitamin B12 illustrates the concept. Many intestinal microorganisms depend on cobamides for metabolic reactions, while only a subset can synthesize them. P. freudenreichii is well recognized for its vitamin B12 biosynthetic capacity, making vitamin metabolism a useful example of how microbial function can extend beyond the organism itself.
For an HCP, the implication is broader than B12 itself. A strain may have value not simply because it is present, but because of what it makes available to the surrounding microbial community.
The Mechanistic Breakthrough: Microbiome–Immune Signaling
The strongest strain-specific scientific story for P.UF1® comes from peer-reviewed mechanistic research.
In the 2017 Journal of Clinical Investigation paper, researchers identified dihydrolipoamide acetyltransferase (DlaT), a major P.UF1 surface-layer protein, as necessary for induction of the observed Th17 response. The work implicated SIGNR1 on dendritic cells in recognition of P.UF1 and regulation of intestinal phagocyte responses.[1] [Preclinical mechanistic evidence; SIGNR1 is a murine receptor in these studies.]
Follow-up work in Gut Microbes showed that P.UF1 increased protective Th17 cells while maintaining IL-10+ regulatory T-cell populations in newborn mice challenged with Listeria monocytogenes. The study also linked P.UF1 with maintenance of microbiota function and B-vitamin metabolites involved in T-cell regulation.[2]
A subsequent Mucosal Immunology paper extended the surface-signaling story to glycosylated large surface-layer protein A (LspA), demonstrating that its interaction with SIGNR1 influenced dendritic-cell transcriptomic and metabolomic programs in preclinical models.[3]
Taken together, the research describes a remarkably specific biological conversation: bacterial surface structures → dendritic-cell recognition → downstream immune programming.
Referenced Preclinical Research: More Than One Model
The preclinical story is not based on a single experiment. The ProGenr8® program includes multiple referenced models examining distinct aspects of P.UF1 biology.
· Neonatal intestinal injury model — P.UF1® was associated with reduced expression of pro-inflammatory genes and mitigation of NEC-like injury in neonatal mice.[1]
· Listeria challenge model — P.UF1® increased protective Th17 cells, maintained regulatory T-cell populations and supported microbiota/metabolite function during intestinal pathogen challenge.[2]
· Chemically induced colitis model — the supplied research materials report reduced weight loss and diarrhea and improved colitis scores in P.UF1®-treated mice.
Can It Survive the Journey?
Function only matters if the organism can be delivered. In vitro testing supplied for P.UF1® reports high survival under acid, bile, pepsin and pancreatin stress conditions. The ingredient also has supplier-generated room-temperature stability data intended to support practical formulation.
For practitioners, this adds another layer to the functional framework: strain identity, potency and CFUs matter, but so do survivability and the probability that a viable organism reaches the environment where its biological functions are relevant.
Human Clinical Research: The Story Moves Beyond the Bench
P.UF1® also has human clinical research, and that distinction deserves to be stated clearly. The studies should be described according to their actual design and publication/presentation status—not collapsed into a generic “supplier data” category.
Vitamin K1: A Human Metabolic Signal
In a randomized, double-blind, placebo-controlled four-week study presented in the ProGenr8® research materials, 20 adults consumed either 10 billion CFU P.UF1® or placebo. Plasma vitamin K1 increased 29% from baseline after two weeks and 52% after four weeks in the P.UF1® group; the corresponding placebo changes were 22% and 27%.
The study is especially interesting conceptually because it asks whether a metabolically active probiotic can be associated with a measurable change in a circulating nutrient biomarker. Interpretation of comparative efficacy should depend on the complete statistical analysis, not baseline percentage changes alone.
Immune Health, Quality of Life, Mood and Sleep
The 2026 ProGenr8® presentation also reports a double-blind, placebo-controlled human clinical study in 55 teachers receiving 10 billion CFU P.UF1® for four months. The presented outcomes include immune-related quality of life, URTI-impacted sick days, state and trait anxiety, and subjective sleep quality.
Among the presented findings, cumulative WURSS quality-of-life burden was reported 35% lower, and URTI-impacted sick days were reported 38% lower. The presentation also reports statistically significant changes in state and trait anxiety over time and improvement in subjective sleep quality.
Separately, a randomized, double-blind, placebo-controlled, parallel clinical trial of ProGenr8® in teachers prone to upper respiratory tract infections is registered as NCT07033754 / CTRI/2025/06/088564, with a 120-day intervention and WURSS-21-based immune-health outcomes.[4]
A Better Framework for Evaluating Probiotics
P.UF1® illustrates why the future of probiotic formulation may be less about winning a CFU-count competition and more about deliberately selecting microbial functions.
· STRAIN — Is the organism characterized at the strain level?
· SURVIVAL — Can it tolerate formulation, storage and gastrointestinal stress?
· METABOLISM — Is the organism metabolically active in the intestinal environment?
· GENERATION — Which vitamins, short-chain fatty acids, amino-acid-related compounds or other metabolites can it contribute?
· CROSS-FEEDING — How might those metabolites influence the surrounding microbial community?
· SIGNALING — Are organism–host communication pathways characterized?
· EVIDENCE — What has been demonstrated mechanistically, preclinically and clinically?
That is a much richer clinical question than simply asking how many billions are in the capsule.
Why Healthgevity Selected ProGenr8® for GUTgevity™
FIRST HCP ACCESS TO PROGENR8® P.UF1®
Healthgevity is the first healthcare-practitioner brand to commercialize ProGenr8® P.UF1® and holds exclusive access to the ingredient within the HCP channel.
For Healthgevity practitioners, this means first access to a probiotic strain with a distinctly different scientific story—one that extends beyond viability and CFU count into microbial metabolism, nutrient and metabolite generation, microbial cross-feeding and microbiome–immune signaling.
P.UF1® represents a function-first approach to probiotic selection: evaluating not only whether a microorganism survives gastrointestinal transit, but what biological capabilities it brings to the intestinal ecosystem.
SURVIVE → METABOLIZE → GENERATE → CROSS-FEED → SIGNAL
This first-to-market HCP introduction gives practitioners an opportunity to incorporate this emerging probiotic science into clinical nutrition strategies through Healthgevity’s GUTgevity™ ecosystem approach.
The Bigger Idea
The first generation of probiotics taught us to look for beneficial organisms.
The next generation asks what those organisms actually do.
What do they make? Which other microbes do they support? Which host pathways do they engage? What happens when those functions are studied in biological models—and ultimately in people?
P.UF1® is a compelling example of that evolution because its story does not begin and end with a species name or CFU count. It connects microbial metabolism, cross-feeding, immune signaling and human research in a single strain-specific program.
Not simply: How many CFUs?
But: What are those CFUs doing?
References
1. Colliou N, Ge Y, Sahay B, et al. Commensal Propionibacterium strain UF1 mitigates intestinal inflammation via Th17 cell regulation. J Clin Invest. 2017;127(11):3970–3986. doi:10.1172/JCI95376.
2. Colliou N, Ge Y, Gong M, et al. Regulation of Th17 cells by P. UF1 against systemic Listeria monocytogenes infection. Gut Microbes. 2018;9(3):279–287. doi:10.1080/19490976.2017.1417731.
3. Ge Y, et al. Regulating colonic dendritic cells by commensal glycosylated large surface layer protein A to sustain gut homeostasis against pathogenic inflammation. Mucosal Immunol. 2020;13(1):34–46. doi:10.1038/s41385-019-0210-0.
4. ClinicalTrials.gov. NCT07033754. A Randomized, Double-blind, Placebo-controlled, Parallel Clinical Study to Assess the Effect of ProGenr8™ (Probiotic Supplement) on Immune Health in Teachers Prone to Upper Respiratory Tract Infection (URTI). Also registered as CTRI/2025/06/088564.
5. SCHISM Bioworks. ProGenr8® Introduction. June 2026. Research presentation supplied to Healthgevity; includes P.UF1® metabolic, preclinical, vitamin K1 and teacher clinical-study materials.
HCP Disclaimer
This material is intended for healthcare professional education only. It is not intended to diagnose, treat, cure or prevent any disease and is not a substitute for independent clinical judgment or individualized patient care. Preclinical findings should not be interpreted as established clinical outcomes in humans.